[1] |
Hayes BH, Haberling DL, Kennedy JL. et al. Burden of pneumonia-associated hospitalizations: United States, 2001-2014[J]. Chest, 2018, 153(2):427-437.
doi: 10.1016/j.chest.2017.09.041
URL
|
[2] |
蒋钟吉, 吴劲松, 刘雪燕, 等. 深圳某三甲医院2019年ICU病原菌分布及耐药性分析[J]. 中国抗生素杂志, 2021, 46(8):795-799.
|
[3] |
Lin MF, Lan CY. Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside[J]. World J Clin Cases, 2014, 2(12):787-814.
doi: 10.12998/wjcc.v2.i12.787
URL
|
[4] |
Eveillard M, Kempf M, Belmonte O. et al. Reservoirs of Acinetobacter baumannii outside the hospital and potential involvement in emerging human community-acquired infections[J]. Int J Infect Dis, 2013, 17(10): e802-e825.
doi: 10.1016/j.ijid.2013.03.021
URL
|
[5] |
Tacconelli E, Carrara E, Savoldi A. et al. Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis[J]. Lancet Infect Dis, 2018, 18(3):318-327.
doi: S1473-3099(17)30753-3
pmid: 29276051
|
[6] |
瞿介明, 曹彬. 中国成人社区获得性肺炎诊断和治疗指南(2016年版)[J]. 中华结核和呼吸杂志, 2016, 39(4):253-279.
|
[7] |
王明贵, Guan X, He L. 等. 广泛耐药革兰阴性菌感染的实验诊断、抗菌治疗及医院感染控制:中国专家共识[J]. 中国感染与化疗杂志, 2017, 17(1):82-92.
|
[8] |
赵清贵, 张险峰. 某三甲医院呼吸内科革兰阴性杆菌的耐药情况分析[J]. 国际检验医学杂志, 2021, 42(6):744-746.
|
[9] |
刘超, 张丽红. 医院与社区获得性肺炎病原菌分布及耐药性变化趋势[J]. 中国卫生检验杂志, 2017, 27(18):2721-2725.
|
[10] |
Davis JS, McMillan M, Swaminathan A. et al. A 16-year prospective study of community-onset bacteremic Acinetobacter pneumonia: Low mortality with appropriate initial empirical antibiotic protocols[J]. Chest, 2014, 146(4):1038-1045.
doi: 10.1378/chest.13-3065
URL
|
[11] |
Meumann EM, Anstey NM, Currie BJ. et al. Genomic epidemiology of severe community-onset Acinetobacter baumannii infection[J]. Microb Genom, 2019, 5(3):e000258.
|
[12] |
2019年全国细菌耐药监测报告[J]. 中国合理用药探索, 2021, 18(3):1-11.
|
[13] |
Lee CR, Lee JH, Park M. et al. Biology of Acinetobacter baumannii: Pathogenesis, antibiotic resistance mechanisms, and prospective treatment options[J]. Front Cell Infect Microbiol, 2017, 7:55.
|
[14] |
Wang Q, Wang Z, Zhang F. et al. Long-term continuous antimicrobial resistance surveillance among Nosocomial Gram-Negative Bacilli in China from 2010 to 2018 (CMSS)[J]. Infect Drug Resist, 2020, 13:2617-2629.
doi: 10.2147/IDR.S253104
pmid: 32801799
|
[15] |
Kengkla K, Kongpakwattana K, Saokaew S. et al. Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: A systematic review and network meta-analysis[J]. J Antimicrob Chemother, 2018, 73(1): 22-32.
doi: 10.1093/jac/dkx368
pmid: 29069421
|
[16] |
Liu J, Shu Y, Zhu F. et al. Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: A systematic review and network meta-analysis[J]. J Glob Antimicrob Resist, 2021, 24: 136-147.
doi: 10.1016/j.jgar.2020.08.021
URL
|
[17] |
Delgado-Valverde M, Conejo M, Serrano L. et al. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia[J]. J Antimicrob Chemother, 2020, 75(7): 1840-1849.
doi: 10.1093/jac/dkaa117
pmid: 32277821
|
[18] |
Heaney M, Mahoney MV, Gallagher JC. Eravacycline: The tetracyclines strike back[J]. Ann Pharmacother, 2019, 53(11): 1124-1135.
doi: 10.1177/1060028019850173
pmid: 31081341
|
[19] |
Gordillo Altamirano F, Forsyth JH, Patwa R. et al. Bacteriophage-resistant Acinetobacter baumannii are resensitized to antimicrobials[J]. Nat Microbiol, 2021, 6(2):157-161.
doi: 10.1038/s41564-020-00830-7
pmid: 33432151
|
[20] |
Hetta HF, Al-Kadmy I, Khazaal SS. et al. Antibiofilm and antivirulence potential of silver nanoparticles against multidrug-resistant Acinetobacter baumannii[J]. Sci Rep, 2021, 11(1): 10751.
doi: 10.1038/s41598-021-90208-4
URL
|